SCHEDULE 14A INFORMATION
(Rule 14a-101)
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934
Filed by the Registrant x Filed by a Party other than the Registrant ¨
Check the appropriate box:
| ¨ | Preliminary Proxy Statement | |
| ¨ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |
| ¨ | Definitive Proxy Statement | |
| x | Definitive Additional Materials | |
| ¨ | Soliciting Material under §240.14a-12 | |
Orexigen Therapeutics, Inc.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy Statement, if other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| x | No fee required. | |||
| ¨ | Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. | |||
| (1) | Title of each class of securities to which transaction applies:
| |||
| (2) | Aggregate number of securities to which transaction applies:
| |||
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
| |||
| (4) | Proposed maximum aggregate value of transaction:
| |||
| (5) | Total fee paid:
| |||
| ¨ | Fee paid previously with preliminary materials. | |||
| ¨ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. | |||
| (1) | Amount Previously Paid:
| |||
| (2) | Form, Schedule or Registration Statement No.:
| |||
| (3) | Filing Party:
| |||
| (4) | Date Filed:
| |||
3344 N. Torrey Pines Court, Suite 200
La Jolla, California 92037
SUPPLEMENT TO THE PROXY STATEMENT
FOR THE 2013 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON JUNE 5, 2013
The purpose of this supplement, dated May 23, 2013 (this “Supplement”), to the definitive proxy statement (the “Proxy Statement”) of Orexigen Therapeutics, Inc. (the “Company”), filed with the Securities and Exchange Commission on April 23, 2013, relating to the Company’s 2013 annual meeting of stockholders to be held on June 5, 2013, is to clarify the description of the attendance by directors at meetings of the board of directors of the Company appearing on page 10 of the Proxy Statement.
The following paragraph replaces in whole the paragraph captioned “Board of Directors Meetings,” under “Proposal 1: Election of Directors” in the Proxy Statement:
“Board of Directors Meetings
During the fiscal year 2012, our board of directors met eight times, including telephonic meetings, and acted by unanimous written consent two times. All incumbent directors attended at least 75% of the aggregate number of meetings of the board and the committees on which they served, during the periods in which they served.”
Except as described above, this Supplement does not modify, amend, supplement or otherwise affect the Proxy Statement.